Cell No. : Cell Name
RCB1184 : Lu-165
update : 2022/03/30
|
| Comment | Producing high level of anti-diuretic hormone. Application consideration |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Terasaki, Takeo
|
| Originator |
Terasaki, Takeo
|
| Year of deposit |
1995
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
50 years
|
| Tissue |
lung, lymph node meta
|
| Disease name |
small cell carcinoma
|
| Metastastatic ability |
Yes
|
| Metastatsd tissue |
lymph node
|
| Classification |
cancer
|
| Year of origin |
1991
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_1391
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
37-107(50) : /39(1),40(6),41(17),42(13),43(6)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
5
|
| User's Publication |
8
|
| Reference |
|
3152
Coulson, J M, Stanley J, Woll, P J
Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer.
Br J Cancer
1999
80:1935-44
PubMed ID: 10471042
DOI: 10.1038/sj.bjc.6690623
|
|
3154
Coulson, J M, Fiskerstrand, C E, Woll, P J, Quinn, J P
Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer.
Cancer Res
1999
59:5123-7
PubMed ID: 10537286
|
|
3153
Coulson, J M, Fiskerstrand, C E, Woll, P J, Quinn, J P
E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer
Biochem J
1999
344:961-970
PubMed ID: 10585887
|
|
3150
Tanaka K, Terasaki T
Development and elongation of neurite-like outgrowth on small cell lung cancer cell lines
Oncogene
1997
88:176-183
PubMed ID: 9119746
DOI: 10.1111/j.1349-7006.1997.tb00363.x
|
|
1974
Terasaki T, Matsuno Y, Shimosato Y, Yamaguchi K, Ichinose H, Nagatsu T, Kato K
Establishment of a human small cell lung cancer cell line producing a large amount of anti-diuretic hormone.
Jpn J Cancer Res (--> Cancer Sci)
1994
85:718-22
PubMed ID: 8071114
DOI: 10.1111/j.1349-7006.1994.tb02420.x
|
| User's Publication |
|
17037
Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, Martín-Tejera JF, Llabata P, Oaknin A, Saigi M, Piulats JM, Matias-Guiu X, Medina PP, Vidal A, Villanueva A, Sanchez-Cespedes M.
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
Nat Commun
2021
12(1):4319
PubMed ID: 34262032
DOI: 10.1038/s41467-021-24618-3
|
|
9502
Morita M, Sato T, Nomura M, Sakamoto Y, Inoue Y, Tanaka R, Ito S, Kurosawa K, Yamaguchi K, Sugiura Y, Takizaki H, Yamashita Y, Katakura R, Sato I, Kawai M, Okada Y, Watanabe H, Kondoh G, Matsumoto S, Kishimoto A, Obata M, Matsumoto M, Fukuhara T, Motohashi H, Suematsu M, Komatsu M, Nakayama KI, Watanabe T, Soga T, Shima H, Maemondo M, Tanuma N.
PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth.
Cancer Cell
2018
33:355-367.e7
PubMed ID: 29533781
DOI: 10.1016/j.ccell.2018.02.004
|
|
12940
Ohta T, Mita M, Hishinuma S, Ishii-Nozawa R, Takahashi K, Shoji M.
Inhibition of Ectopic Arginine Vasopressin Production by Phenytoin in the Small Cell Lung Cancer Cell Line Lu-165
Front Endocrinol (Lausanne)
2017
8:94
PubMed ID: 28503166
DOI: 10.3389/fendo.2017.00094
|
|
9873
Kato F, Fiorentino FP, Alibés A, Perucho M, Sánchez-Céspedes M, Kohno T, Yokota J.
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Oncotarget
2016
7:77378-77388
PubMed ID: 27764802
DOI: 10.18632/oncotarget.12671
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
|
16489
Seike M, Kondo T, Fujii K, Okano T, Yamada T, Matsuno Y, Gemma A, Kudoh S, Hirohashi S.
Proteomic signatures for histological types of lung cancer
Proteomics
2005
5(11):2939-48
PubMed ID: 15996008
DOI: 10.1002/pmic.200401166
|
|
2929
Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, Nakagawa K, Nomura H, Ishikawa Y
Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles
Lancet
2004
63:775-781
PubMed ID: 15016488
DOI: 10.1016/S0140-6736(04)15693-6
|
|
3338
Seike, Masahiro, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Gemma, Akihiko, Kudoh, Shoji, Hirohashi, Setsuo
Proteomic signature of human cancer cells.
Proteomics
2004
4:2776-88
PubMed ID: 15352251
DOI: 10.1002/pmic.200300795
|
Back
Top
CELL BANK Website
